Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer

NCT01033032 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT01033032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01033032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2009
Completion date
October 31, 2014
Enrollment
78 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer